EGFR-IN-5

Target: This ligand targets the epidermal growth factor receptor (EGFR) tyrosine kinase domain in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for the epidermal growth factor receptor (EGFR) tyrosine kinase domain. In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings the epidermal growth factor receptor (EGFR) tyrosine kinase domain into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• EGFR-Directed PROTAC Design: EGFR-IN-5 can serve as the EGFR-binding ligand moiety in PROTACs to recruit an E3 ligase and induce EGFR proximity-driven ubiquitination. This enables systematic evaluation of degradation efficiency across EGFR mutants, expression levels, and signaling states, supporting mechanistic studies of receptor turnover and pathway suppression.

• Optimizing Degrader Potency: EGFR-IN-5–based PROTACs can be engineered with varied linker lengths and attachment chemistries to tune ternary complex formation and ubiquitination kinetics. Researchers can compare degradation potency versus EGFR inhibition, identifying conditions that preferentially drive proteasome-dependent loss of EGFR rather than transient pathway blockade.

• Mechanistic Studies of Ubiquitination: Using EGFR-IN-5 in targeted degradation workflows allows interrogation of the ubiquitin-proteasome pathway requirements for EGFR disposal. Experiments can include E3 ligase swapping, proteasome inhibition controls, and time-resolved immunoblotting to map degradation onset, residence effects, and dependence on endocytic trafficking.

• Target Specificity and Resistance Mapping: EGFR-IN-5–derived PROTACs can be used to assess selectivity across EGFR family members and related kinases by monitoring degradation profiles and downstream signaling markers. This supports investigation of resistance mechanisms, including altered ligand engagement or E3 recruitment, guiding rational redesign for robust EGFR degradation.

EGFR-IN-5 is a EGFR kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of EGFR-IN-5 is characterized by primary or secondary amine/basic nitrogen centers; phenol or alcohol functionality; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.